Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 30, 2021
Distillery Therapeutics
SLC12A5, Rho kinase as targets for mutation-associated intellectual disability
DISEASE CATEGORY: Neurology
INDICATION: Cognitive dysfunction Inhibiting SLC12A5, a cation-Cl− cotransporter, or Rho kinase could treat intellectual disability associated with
INDICATION: Cognitive dysfunction Inhibiting SLC12A5, a cation-Cl− cotransporter, or Rho kinase could treat intellectual disability associated with
BioCentury | Oct 12, 2018
Emerging Company Profile
Spinogenix’s Spine Craft
Spinogenix is rebuilding dendritic spines, cognition in neurodegeneration
Items per page:
1 - 10 of 121